Author

Migliorino MR

medical Oncologist-San Camillo Forlanini Hospital - Cited by 9,127 - lung cancer

Biography

Specialista in Oncology Medica e Pneumology Responsabile UOSD Pneumologia Oncologica A.O. San Camillo-Forlanini Roma.Responsible for hospitalization in ordinary hospitalization and day-hospital for patients undergoing diagnostic assessment for lung cancer or undergoing chemotherapy treatment; - Principal Investigator of Phase 2-3 clinical trials for lung cancer;    
Title
Cited by
Year
Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and outcomes with nivolumab in pretreated non-small cell lung cancer (NSCLC): a large retrospective …
A Russo, M Russano, T Franchina, MR Migliorino, G Aprile, G Mansueto, ...Advances in therapy 37, 1145-1155, 2020202
103
2020
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer
L Landi, F D’Incà, A Gelibter, R Chiari, F Grossi, A Delmonte, A Passaro, ...Journal for immunotherapy of cancer 7, 1-9, 2019201
96
2019
First-line pembrolizumab in advanced non–small cell lung cancer patients with poor performance status
F Facchinetti, G Mazzaschi, F Barbieri, F Passiglia, F Mazzoni, R Berardi, ...European Journal of Cancer 130, 155-167, 2020202
93
2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/Programmed cell death …
A Cortellini, M Bersanelli, D Santini, S Buti, M Tiseo, K Cannita, F Perrone, ...European Journal of Cancer 128, 17-26, 2020202
76
2020
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab …
A Cortellini, M Di Maio, O Nigro, A Leonetti, DL Cortinovis, JGJV Aerts, ...Journal for immunotherapy of cancer 9 (4), 2021202
76
2021
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of≥ 50%
A Cortellini, M Tiseo, GL Banna, F Cappuzzo, JGJV Aerts, F Barbieri, ...Cancer Immunology, Immunotherapy 69, 2209-2221, 2020202
63
2020
Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression≥ 50%: a multicenter study with external validation
A Cortellini, B Ricciuti, M Tiseo, E Bria, GL Banna, JGJV Aerts, F Barbieri, ...Journal for immunotherapy of cancer 8 (2), 2020202
58
2020
Immune-related adverse events of pembrolizumab in a large real-world cohort of patients with NSCLC with a PD-L1 expression≥ 50% and their relationship with clinical outcomes
A Cortellini, A Friedlaender, GL Banna, G Porzio, M Bersanelli, ...Clinical lung cancer 21 (6), 498-508. e2, 2020202
51
2020
Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and EGFR …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, A Chawla, ...Drugs 81, 257-266, 2021202
51
2021
Durvalumab after sequential chemoradiotherapy in stage III, unresectable NSCLC: the phase 2 PACIFIC-6 trial
MC Garassino, J Mazieres, M Reck, C Chouaid, H Bischoff, N Reinmuth, ...Journal of Thoracic Oncology 17 (12), 1415-1427, 202232202
32
2022
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study
A Cortellini, A De Giglio, K Cannita, DL Cortinovis, R Cornelissen, ...Thoracic Cancer 12 (6), 880-889, 2021202
30
2021
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy
S Buti, M Bersanelli, F Perrone, S Bracarda, M Di Maio, R Giusti, O Nigro, ...European Journal of Cancer 150, 4-231, 2021202
22
2021
Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes
A Cortellini, A Leonetti, A Catino, P Pizzutillo, B Ricciuti, A De Giglio, ...Clinical and Translational Oncology , 844-851, 2020202
22
2020
Updated overall survival (OS) from extended follow up in ARCHER 1050: a randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts …
TSK Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa, S Niho, R Linke, ...Annals of Oncology 30, ix200-ix201, 2019201
16
2019
Post-progression outcomes of NSCLC patients with PD-L1 expression≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study
A Cortellini, K Cannita, M Tiseo, DL Cortinovis, JGJV Aerts, C Baldessari, ...European Journal of Cancer 148, 24-35, 2021202
15
2021
Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
S Popat, HA Jung, SY Lee, MJ Hochmair, SH Lee, C Escriu, MK Lee, ...Lung Cancer 162, 9-, 2021202
15
2021
Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study
F de Marinis, KK Laktionov, A Poltoratskiy, I Egorova, M Hochmair, ...Lung Cancer 152, 127-134, 2021202
14
2021
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDIa-2)
M Bersanelli, D Giannarelli, U De Giorgi, S Pignata, M Di Maio, ...Journal for Immunotherapy of Cancer 9 (5), 2021202
13
2021
OA02. 07 phase 3 ALUR Study of Alectinib in pretreated ALK+ NSCLC: final efficacy, safety and targeted genomic sequencing analyses
J Wolf, Å Helland, I Oh, MR Migliorino, R Dziadziuszko, JDC Carpeno, ...Journal of Thoracic Oncology 14 (10), S210, 2019201
12
2019
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving nivolumab
F Pantano, M Russano, A Berruti, G Mansueto, MR Migliorino, V Adamo, ...Expert Opinion on Biological Therapy 20 (3), 319-326, 2020202
11
2020

Referred From: https://scholar.google.com/citations?user=_UpjOwgAAAAJ&hl=en

Cited by
Citations 9127
h-index 32
i10-index 62
Recommended Journals
Open Access Journals